Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age65-85
SponsorUniversity of Colorado, Denver
About this trial
This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.
Eligibility criteria
Qualifiers
Aged 65-85 years & be male, female, or non-binary
Generally healthy
Have an identified support person
Capacity to Consent
Disqualifiers
Unstable medical condition
Risk for hypertensive crisis (screening blood pressure >140/90 mmHg)
Significant central nervous system (CNS) pathology
Primary psychotic or affective psychotic disorders
Trial design
Treatments tested in this trial
- Psilocybin (Usona Institute)
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Institute on Aging (NIA)
Collaborator
University of California, San Francisco
Collaborator
Emory University
Collaborator
Dana-Farber Cancer Institute
Collaborator
NYU Langone Health
Collaborator
University of Nebraska
Collaborator
Source ClinicalTrials.gov